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It is usually accepted that an older age ofmenopause is associated with an increased risk of breast cancer. This is often interpreted as a statement about postmenopausal women; however, some authors, eg ref. 1 We begin with a survey ofthe literature: comparison of reported studies is difficult because of considerable variations in the definitions of menstrual status (as well as absence and vagueness of definitions), the frequent absence of any "menopausal" category, and a lack of age-specific figures. The only clear consensus is that there is a higher risk among women aged 50-54 who are still menstruating than among those who are postmenopausal.
Later we propose a modification of the "two linear component" model for age incidence: this includes increased incidence at the time of the menopause and a subsequent deficit. The intention is to test this model using data from the Edinburgh Breast Screening Trial, and the suitability for this purpose of the data which are being collected is discussed.
Survey of the literature
We have reviewed the literature for information on The most positive evidence of a trend of risk in this age range with age at menopause comes from a recent study in Canada. 6 Unfortunately, the authors do not give details of their definitions of menstrual status and there is a large number of women with missing or excluded data. Also the cases were interviewed using a modified questionnaire in the autumn of 1978 to obtain retrospective information of their state in January 1977. In the absence of further information it is not possible to assess the effect of these factors.
We conclude that there is little evidence that the time of the menopause within the age range 45-54 makes a difference to the risk in postmenopausal women aged < 65. The relation between age at menopause and age at diagnosis for them is, as stated,4 "exceedingly complex". This must be considered alongside the accepted conclusion that among all postmenopausal women without any upper age limit an older age at menopause is associated with increased risk. The refutation of this apparent contradiction must be in terms of either a latent period after the menopause or some other phenomenon applying to women in this age group. The difficulties encountered in comparing studies arising from their use of different menstrual categories has already been mentioned. The problem is particularly important here, and different studies may be reporting apparently conflicting results merely because they are classifying women in the crucial years around the menopause into different menstrual categories. Table 3 gives our own results and shows how differences in definition would have influenced them. Table 4 gives the results from other studies which are available for this question. As There are no studies apart from our own that discuss this question, and so it has to be approached indirectly. Precise definitions are even more important here than they were for question 2, and it is necessary to remember that the gynaecologists warn that the menopause cannot be identified as a present event.2' Some evidence can be obtained from comparing those studies which indicate where they have placed their menopausal category. Table 3 shows the effect of this in our study. Those studies which include the menopausal group in their premenopausal category (eg, 17), tend to show a high relative risk for the premenopausal state. The HIP study which tends to over-report the postmenopausal status gives a reduced risk for the premenopausal state.
A further source of indirect evidence is a quite different series of studies which has examined the risk for oral-contraceptive users, including older current users.18-21 In these studies, some of the older current users may be incorrectly classified as premenopausal when in fact they are menopausal. Jick et alt8 claim that since such women would be at decreased risk these misclassifications would introduce a conservative bias. If, on the other hand, these menopausal women are at increased risk, then the bias would result in inflated relative risks. When we consider that these reports tend to be consistent in showing little evidence of an increased risk associated with use of the pill, and yet two18 21 quote high relative risks for current users aged over 50 (15.5 and 3'8 respectively, which are statistically significant), a hypothesis which explains a systematic bias is very attractive.
An association, whether causal or not, between increased detection of existing tumours and the menopause would lead to a deficit in the few years after the menopause, and this would lead to a positive correlation between age at menopause and age at diagnosis. This has been reported by Chen;22 in our own study there was a statistically significant though small positive correlation between age at menopause and age at diagnosis (r=0'1, p=0-012).
In this review we have found that the increase in risk usually attributed to a late menopause is not particularly apparent in the decade or so after the menopause is completed; on the other hand, we have also found that older women who are still menstruating are at increased risk at the time and that it is possible to interpret this as an increase in risk at the time of the menopause. We now proceed to see whether there is a modification of existing mathematical models which will account for these features.
A modified mathematical model
For female breast cancer it is well known (eg, refs 23-26) that the age-incidence curve breaks between the ages of 45 and 55 with a plateau until it rises again for women over 60. The break occurs at the age of the menopause and is usually attributed to it. The break is not merely an artefact of birth cohort effects25 but if allowance for these effects is made then both Eastern and Western populations have the same basic shape of incidence curve. When the log-incidence rate is plotted 98 against log age this curve has two linear components with the change from one to the other at the menopausal age ( figure) .
The premenopausal part of this curve is similar to that of other adult cancers and is consistent with the equation I(t) oc tk where 1(t) is the age-specific incidence rate at age t and k is between 4 and 5. This in turn is consistent with a biological model of two (or multi-) stage carginogenesis with approximately constant exposure over each time interval to initiating and promoting factors and with a growth rate for established tumours which is not time or age dependent.27 28 Doll et a129 modified the equation for lung cancer by replacing the chronological age in years "t" by the time spent as a smoker; and a similar modification for breast cancer replaces "t" by the time from menarche. It is currently believed that the hormone profile during the reproductive period is related to both stages of development: at the first stage either as initiator or providing a suitable environment for some exogenous initiator and then in the second stage as promoter. The particular hormones involved are not known, though it seems likely that oestrogens are involved. A longer reproductive period for women who have an earlier menarche and/or a late menopause will lead to a longer time of "exposure" and hence a longer steep section of the age-incidence path and explain the epidemiological significance of early menarche and late menopause.
Various authors have modified the mathematical or biological models so as to include the second part of the curve. These provide excellent fits to population incidence data over a wide age range and are able to account satisfactorily for known epidemiological risk factors. One would not normally criticise the fit that is achieved in any one instance. In the present context, however, it is interesting that of seven sets of Models for age-incidence (A and B denote younger and older ages at menopause). *-* shows where the effect of an older age at menopause is disguised.
Freda E Alexander and M Maureen Roberts population data compared with fitted models,27 30 in all but one (Osaka) the pattern of observed rates is flatter around the age of 50 than the fitted model. They also predict that the effect of a late menopause will be seen at all times subsequently and they certainly do not suggest an increased incidence at the time of the menopause.
These extra features can be explained by modifying the basic model to incorporate increased growth of existing tumours at the time of the menopause. This leads to increased incidence at that time and consequently decreased incidence in the short term afterwards. The qualitative effects of superimposing this on the basic model are illustrated in the figure. For the purpose of the model the changes are sharp and immediate but this is certainly an oversimplification.
The modification can be applied to any more detailed models such as those of Moolgavkar et al and Pike et a127 30 and will have the same ability to explain other known epidemiological risk factors as the underlying model. It will also at least qualitatively explain the features that we have been discussing.
Discussion
Evidence has been found in our own study and in the literature that the increased risk associated with an older age of menopause is not very evident until a considerable time has lapsed from the menopause; however, older premenopausal and perimenopausal women are at increased current risk. Current mathematical models give good overall fit to population age-incidence curves but they tend to underestimate the incidence at the younger end of the age range 45-55 and overestimate it at the end of this age range.
A hypothesis has been suggested which explains these features: that there is an increase in growth rate for existing tumours at the time of the menopause.
This will lead to an increase in incidence at the time of the menopause and a corresponding deficit shortly afterwards; the effect of super-imposing this on the basic model ofuniform increased risk following from a longer length of time spent in the most favourable period for tumour development (menarchemenopause) leads to the confusion in the reported effects of a late menopause in the years shortly after it has taken place and hence in its effect being observed primarily in older women. It also explains the increased current risk for perimenopausal women and provides for the observed flattening of the age incidence curves relative to fitted models at ages 
